Riverstone Holdings (AP4) Fair Value & Analysis
Healthcare · SG · Market cap 1.3B SGD
Fair value as of: Jul 4, 2026
From 26 valuation models · updated today
Share price −5.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.6198 SGD – 0.9700 SGD · fair‑value band 0.6700 SGD – 1.22 SGD · the 0.8500 SGD price screens below the 0.9800 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Riverstone Holdings (AP4) currently trades at 0.8500 SGD, while our model-based Fair Value estimate is 0.9800 SGD — implying the stock looks roughly 15.3% undervalued today. We read business quality at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Riverstone Holdings generated revenue of 957M SGD at a net margin of 20.1%. Revenue declined 15.1% year over year. It earns a return on equity of 13.6%. The stock trades on a trailing P/E of 21.3. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Riverstone Holdings Limited, an investment holding company, engages in the manufacture and distribution of cleanroom and healthcare gloves in Malaysia, Thailand, and China. The company offers cleanroom gloves, healthcare gloves, cleanroom face masks, fingercots, static shielding bags, face masks, wipers, cleanroom packaging bags, and other cleanroom consumables. It sells its products under the RS brand for use in the hard disk drive and semiconductor industries. It also exports its products to Asia, Europe, and the United States. Riverstone Holdings Limited was founded in 1989 and is based in Singapore.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Riverstone Holdings reported revenue of 995M SGD in FY2025 versus 3.1B SGD in FY2021, a compound −24.6%/yr. Reported net income was 208M SGD in FY2025, compounding −38.1%/yr from FY2021.
Is AP4 fairly valued? → Check now
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| Becton, Dickinson and Company BDX | $149.56 | $117.04 | -22% |
| Alcon Inc ALC | $66.11 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Riverstone Holdings (AP4) undervalued?
What is the fair value of AP4?
What is the quality score of AP4?
What is the revenue of Riverstone Holdings (AP4)?
What is the net profit margin of AP4?
Does Riverstone Holdings pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.